Genor Biopharma Holdings (FRA:67N0) Days Payable: 0.00 (As of Jun. 2025)


FRA:67N0 Genor Biopharma Holdings Ltd FRA:67N0
22 GF Score
Price €0.34
! 1 Warning Sign
View Full Analysis

What is Genor Biopharma Holdings Days Payable?

Genor Biopharma Holdings FRA:67N0 +3.70% 22 Days Payable is 0.00 as of Jun. 2025. GuruFocus rates FRA:67N0 with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Genor Biopharma Holdings's average Accounts Payable for the six months ended in Jun. 2025 was €15.82 Mil. Genor Biopharma Holdings's Cost of Goods Sold for the six months ended in Jun. 2025 was €0.00 Mil.

The historical rank and industry rank for Genor Biopharma Holdings's Days Payable or its related term are showing as below:

FRA:67N0' s Days Payable Range Over the Past 10 Years
Min: 2067.28   Med: 13838.19   Max: 49277.74
Current: 45191.68

During the past 7 years, Genor Biopharma Holdings's highest Days Payable was 49277.74. The lowest was 2067.28. And the median was 13838.19.

FRA:67N0's Days Payable is not ranked
in the Biotechnology industry.
Industry Median: 112.83 vs FRA:67N0: 45191.68

Genor Biopharma Holdings's Days Payable declined from Jun. 2024 (70,631.56) to Jun. 2025 (0.00). It may suggest that Genor Biopharma Holdings accelerated paying its suppliers.

Genor Biopharma Holdings Days Payable Historical Data

* Premium members only.

The historical data trend for Genor Biopharma Holdings's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genor Biopharma Holdings Days Payable Chart

Genor Biopharma Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Days Payable
Get a 7-Day Free Trial 13,838.19 0.00 49,277.74 0.00 30,130.13

Genor Biopharma Holdings Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 70,631.56 19,304.99 0.00

FRA:67N0 vs VRTX, REGN, ALNY: Days Payable Comparison

For the Biotechnology subindustry, Genor Biopharma Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genor Biopharma Holdings Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's Days Payable distribution charts can be found below:

* The bar in red indicates where Genor Biopharma Holdings's Days Payable falls into.


FRA:67N0
22GF Score
Genor Biopharma Holdings Ltd FRA:67N0
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genor Biopharma Holdings Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Genor Biopharma Holdings's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

Days Payable (A: Dec. 2024 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2023 ) + Accounts Payable (A: Dec. 2024 )) / count ) / Cost of Goods Sold (A: Dec. 2024 )*Days in Period
=( (18.193 + 10.864) / 2 ) / 0.176*365
=14.5285 / 0.176*365
=30,130.13

Genor Biopharma Holdings's Days Payable for the quarter that ended in Jun. 2025 is calculated as:

Days Payable (Q: Jun. 2025 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Dec. 2024 ) + Accounts Payable (Q: Jun. 2025 )) / count ) / Cost of Goods Sold (Q: Jun. 2025 )*Days in Period
=( (10.864 + 20.784) / 2 ) / 0*365 / 2
=15.824 / 0*365 / 2
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Genor Biopharma Holdings (FRA:67N0) has a Days Payable of 0.00 as of Jun. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genor Biopharma Holdings and its competitors. Over the past decade, Genor Biopharma Holdings' Days Payable has ranged from 2,067.28 to 49,277.74.
Is Genor Biopharma Holdings' Days Payable too high?
Genor Biopharma Holdings' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 2,067.28 to a high of 49,277.74. Overall, Genor Biopharma Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Genor Biopharma Holdings' Days Payable compare to VRTX and REGN?
Genor Biopharma Holdings' Days Payable of 0.00 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 112.83. Historically, Genor Biopharma Holdings' own Days Payable has ranged from 2,067.28 to 49,277.74 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.83, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genor Biopharma Holdings and its competitors. For the Biotechnology industry, the median Days Payable is 112.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genor Biopharma Holdings's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genor Biopharma Holdings stock overvalued right now?
Genor Biopharma Holdings (FRA:67N0) has a current Days Payable of 0.00. The current Days Payable is 0.00. Genor Biopharma Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Genor Biopharma Holdings (FRA:67N0), the current Days Payable is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genor Biopharma Holdings Business Description

Address 690 Bibo Road, Room 501-02, Building 6, Pudong New District, Shanghai, CHN, 201203
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
22GF Score

Get the complete analysis for FRA:67N0

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.34
Price